Reviewing Aspyra (OTCMKTS:APYI) and Evaxion A/S (NASDAQ:EVAX)

Aspyra (OTCMKTS:APYI) and Evaxion A/S (NASDAQ:EVAX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aspyra and Evaxion A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspyra	0	0	0	0	0.00
Evaxion A/S	1	0	4	1	2.83

Evaxion A/S has a consensus price target of $11.75, indicating a potential upside of 276.60%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Aspyra.

Profitability

This table compares Aspyra and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspyra	N/A	N/A	N/A
Evaxion A/S	N/A	-68.82%	-24.12%

Earnings and Valuation

This table compares Aspyra and Evaxion A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspyra	N/A	N/A	N/A	N/A	N/A
Evaxion A/S	$3.34 million	7.79	-$10.57 million	($0.39)	-8.00

Aspyra has higher earnings, but lower revenue than Evaxion A/S.

Volatility and Risk

Aspyra has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Insider and Institutional Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. 23.9% of Aspyra shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Evaxion A/S beats Aspyra on 7 of the 10 factors compared between the two stocks.

About Aspyra

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.